Exelixis

Exelixis OCF/Debt

The Operating Cash Flow to Debt Ratio of Exelixis (EXEL) as of Nov 22, 2026 is 511.02 %. In the previous year, Operating Cash Flow to Debt Ratio was 366.82 % — a change of 39.31% (higher).

OCF/Debt

511.02 %

YoY

39.31%

Last updated:

Operating Cash Flow to Debt Ratio of Exelixis is 2025 511.02 % . Operating Cash Flow to Debt Ratio of Exelixis was 2024 366.82 % . It decreases by 39.31% higher compared to the previous year.

The Exelixis OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
730.26 USD
Jan 1, 2019
1,038.56 USD
Jan 1, 2020
425.75 USD
Jan 1, 2021
781.72 USD
Jan 1, 2022
190.68 USD
Jan 1, 2023
175.49 USD
Jan 1, 2024
366.82 USD
Jan 1, 2025
511.02 USD
The Exelixis OCF/Debt history
YEAROCF/DebtYoY
511.02 %+39.31%
366.82 %+109.03%
175.49 %-7.97%
190.68 %-75.61%
781.72 %+83.61%
425.75 %-59.01%
1,038.56 %+42.22%
730.26 %+217.44%
230.04 %+110.89%
109.08 %-715.86%
-17.71 %-72.79%
-65.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Exelixis Stock analysis

What does Exelixis do? Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exelixis stock

Operating Cash Flow to Debt Ratio of Exelixis is 511.02 % in 2025.

Operating Cash Flow to Debt Ratio of Exelixis changed from 366.82 % to 511.02 %, representing a 39.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Exelixis since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Exelixis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Exelixis

All Key Metrics — Exelixis